Fluorescence-guided mesorectal nodes harvesting associated with local excision for early rectal cancer: technical notes
Ilaria Benzoni, Martina Fricano, Jessica Borali, Martina Bonafede, Andrea Celotti, Antonio Tarasconi, Valerio Ranieri, Luigi Totaro, Luca Mattia Quarti, Arianna Dendena, Giulia Grizzi, Maria Bonomi, Roberto Grassia, Barbara Frittoli, Gian Luca Baiocchi
Abstract
BACKGROUND: The spread of colorectal cancer screening has increased the percentage of patients with early-stage rectal cancer; at least 30% of patients are diagnosed with a clinical-stage cT1 or pT1 after endoscopic excision. In this subgroup of patients, the real advantage of total mesorectal excision (TME) over local excision (LE) is the ability to remove mesorectal nodes, which are metastatic in less than 20% of cases. METHOD: To solve the unmet need for accurate nodal staging in patients with cT0/cT1, cN0 rectal cancer, we designed a pilot study that associates LE with mesorectal fluorescence-guided nodal sampling. From November 2018 to November 2023, we enrolled a total of ten patients with T1N0M0 rectal cancer. After extensive staging and adequate information, patients underwent endoscopic indocyanine green (ICG) infiltration and transanal local excision associated with laparoscopic fluorescence-guided mesorectal nodal sampling. RESULTS: After a median follow-up of 24 months (range 1-63 months), no case of local or nodal recurrence was observed. All patients were spared from ostomy and lower anterior resection syndrome. CONCLUSIONS: In selected cases of cT0-1cN0 rectal cancer, transanal local excision plus ICG lymph nodal sampling is a feasible surgical option that increases the rate of organ preservation. Further studies are needed to identify the patients most likely to benefit from this minimally invasive strategy.